AML genomes additionally tend to be less mutated relative to the genomes of other cancers (The Cancer Genome Atlas Research Network, 2013), with similar mutational distributions pre-relapse and post-relapse (Li et al., 2016a,b); furthermore, of these mutations, many tend to occur in genes associated with DNA methylation and epigenetic regulation, including DNMT3A, TET1/2, and IDH1/2 (Guillamot et al., 2016). This evidence concerns the gene IDH1 and acute myeloid leukemia.